ZENAS BIOPHARMA, INC.
Last · NASDAQ$24.86-0.30 (-1.19%)close · yahoo · 16h ago
Market cap$1.62B65.2M sh
P/E · TTM-2.6fwd -5.3 · eps -9.63 · loss
Beta-0.88vs S&P 500
Div yield0.00%annual · TTM
52w range
$13.50$44.60
Volume425.0Ksession
Loading chart…
OpenFilings analyst
Our analyst
From latest 10-K · 2026-03-16
- Sbc Revenue High
- Operating Cf Burn
- Net Margin Sharply Negative
- Cash Conversion Weak
- Cash Runway Low
- Accumulated Deficit High
- Rd Intensity High
Red flags
- Sbc Revenue High — SBC/Revenue 263.5%
- Operating Cf Burn — Negative operating cash flow
- Net Margin Sharply Negative — Net margin -3777.4%
- Cash Conversion Weak — Cash conversion (CFO/Rev) -1723.3%
- Cash Runway Low — Cash runway ~0.6 years
- Accumulated Deficit High — Accumulated deficit / equity 316%
- Rd Intensity High — R&D/Revenue 1680.6%
Upcoming earnings
1:30 PM UTC+1
Period
Sep 2026
Est. EPS
−$1.27
Est. revenue
0
Press & signals
- GlobeNewswire
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- GlobeNewswire
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- GlobeNewswire
Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
The rest of this company's wire — with summaries and source links — is part of Pro.
See plansDocuments
FormReporting forFiledFlags